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DAX-1 [dosage-sensitive sex reversal, adrenal hypoplasia con-
genital (AHC) critical region on the X chromosome, gene 1] is
a transcription factor expressed in the adrenal gland and at
all levels of the gonadotrope axis. Inactivating mutations of
DAX1 result in the X-linked form of AHC with associated hy-
pogonadotropic hypogonadism. AHC usually reveals itself as
adrenal failure in early infancy, although a wide range of
phenotypic expression has been reported. We describe a pa-
tient who was diagnosed with adrenal failure at 6 wk of age,
but who experienced recovery of adrenal function of several
months’ duration later in infancy. He subsequently failed to
undergo puberty because of hypogonadotropic hypogonad-
ismofpituitaryorigin,andhewasalsodiagnosedwithschizo-
phrenia in early adulthood. Molecular genetic analyses re-
vealed a complex rearrangement in DAX1, including a 2.2-kb
deletion spanning the entire second exon and a small 27-bp
insertion. The putative protein encoded by this mutated gene
is 429 amino acids long. The initial 389 residues probably
correspond to the wild-type DAX-1 sequence, whereas the last
40 amino acids are presumably completely unrelated, being
transcribed from the intronic sequence adjacent to exon 1. In
vitro functional analyses confirm the absence of repressor
activityexertedbysuchmutantprotein.Thesestudiesexpand
the genotypic and phenotypic spectrum of DAX-1 insuffi-
ciency in humans. (J Clin Endocrinol Metab 87: 4094–4100,
2002)
D
AX-1 [DOSAGE-SENSITIVE SEX reversal, adrenal hy-
poplasia congenital (AHC) critical region on the X chro-
mosome, gene 1] is a member of the orphan nuclear receptor
superfamily (1, 2). It is expressed in the adrenal glands and at
all levels of the hypothalamo-pituitary-gonadal axis (3, 4). This
pattern of expression is consistent with a role for DAX-1 in the
development and function of the adrenal gland, as well as in
reproduction. It is also reminiscent of the expression pattern of
steroidogenic factor 1 (SF-1), a transcription factor involved in
the regulation of steroidogenic enzymes as well as that of go-
nadotropic hormones (5, 6). Duplication of DAX-1 is associated
with male-to-female sex reversal (7, 8). On the other hand,
inactivating mutations of this gene cause the X-linked form, so
called cytomegalic variant, of AHC (1, 2). This rare syndrome
results in adrenal failure and is usually lethal in early infancy
unless recognized and treated. Affected individuals commonly
fail to undergo puberty later in life (9) because of an association
with hypogonadotropic hypogonadism (10).
In vitro data suggest that one function of DAX-1 is to act as
a repressor of SF-1-stimulated transcription (11). However, the
phenotype of the Ahch (mouse equivalent of DAX1) knockout
mouse (12), similar to a recently described human case of
DAX-1 mutation (13), also implicates DAX-1 in the control of
spermatogenesis.Todate,anumberofframeshiftandnonsense
mutations of DAX-1 have been described (summarized in Refs.
14 and 15). They all result in a truncated protein lacking its
carboxy-terminal end. This pattern is fully consistent with the
localization of a repression domain in that part of the DAX-1
protein (11, 16). Fewer missense mutations have been de-
scribed, also localized at the carboxy-terminal end of the
molecule.
We report here the clinical features of a patient who pre-
sented an unusual evolution of adrenal failure in infancy,
and complete hypogonadotropic hypogonadism of pituitary
origin later in life. This patient harbors a complex mutation
of DAX-1, combining a large deletion including the entire
second exon of the gene with a small insertion of 27 bp. In
vitro studies confirmed the complete lack of functional re-
pression of SF-1-mediated transcription resulting from this
mutation.Thephenotypeofthispatient,whopresentedwith
a gradual progression of adrenal insufficiency early in child-
hood, confirms the existence of a wide spectrum of clinical
presentations of AHC (17, 18) and is therefore important for
the appropriate clinical management of the syndrome.
Subjects and Methods
Case report
The proband was a male infant born after an uneventful full-term
pregnancy, second son of two. There is no family history of somatic
Abbreviations: AHC, Adrenal hypoplasia congenita; DAX-1, dosage-
sensitive sex reversal, AHC critical region on the X chromosome, gene
1; DBD, DNA binding domain; SF-1, steroidogenic factor 1; StAR, ste-
roidogenic acute regulatory protein.
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4094disorder, and in particular no history of endocrinopathy of any sort.
However, family history is remarkable for the presence in the patient’s
mother of an unspecified psychiatric illness, which required several
hospital stays during the patient’s childhood. The mother has now been
stable for several years on haloperidol decanoate treatment.
In wk 6 of life, the proband presented with vomiting, dehydration,
hyponatremia,andhyperkalemiawithnormalrenalfunction.Thework-
up showed elevated plasma levels of ACTH at 172 ng/liter, decreased
levels of plasma aldosterone and markedly decreased levels of urinary
17-ketosteroids, tetrahydrocortisone, and tetrahydrocortisol. There was
no response of plasma aldosterone or of the urinary metabolites to
cosynthropin administration (250 mg iv). A diagnosis of adrenal insuf-
ficiency was made. He subsequently did well on cortisone and deoxy-
corticosterone acetate replacement therapy associated with salt supple-
mentation, his plasma ACTH levels decreasing to 73 ng/liter.
At age 2 yr and 6 months, he was evaluated for failure to thrive
possibly due to exogenous glucocorticoid excess. Under no hormonal
therapy,baselineACTHlevelswere1340ng/literinthefaceofacortisol
value of 480 nmol/liter (normal range: 200–700 nmol/liter). Stimulation
with cosynthropin, 250 mg iv, induced only a marginal rise in cortisol
to 504 nmol/liter. The patient was then considered to have relative
primary adrenal insufficiency. Hormonal replacement was withheld,
and the patient performed well clinically. However, after more than 6
months on no hormone supplementation, he experienced recurrent
vomiting accompanied by dehydration, hyponatremia, and hyperkale-
mia. Therefore, hormonal replacement therapy was resumed. The pa-
tient, now 25 yr old, has been under this medication ever since, lately
as hydrocortisone and fludrocortisone.
Hismedicalhistoryremaineduneventfuluntilage16yr,whenhewas
evaluated for delayed puberty. His testicular volume was 4 ml bilater-
ally. Biochemical work-up showed low gonadotropin levels: LH was 0.6
IU/liter (normal adult range: 3.0–13 IU/liter) and FSH 1.0 IU/liter
(normal adult range: 2.0–12 IU/liter), in the face of a low circulating
testosterone concentration of 2.1 nmol/liter (normal adult range: 12.0–
42.0 nmol/liter). Anatomy of the hypothalamo-pituitary region was
normal on magnetic resonance imaging exam, and formal testing dis-
closed a normal sense of smell, all findings consistent with isolated
GnRH deficiency. Together with the primary adrenal insufficiency oc-
curring early in childhood, it allowed to make the diagnosis of DAX-1
deficiency (2, 9). The patient has been subsequently treated with
monthly testosterone ester injections (250 mg, im).
Further assessment of the hypogonadism was performed by testing
with pulsatile GnRH therapy at age 24 yr (5, then 10 mg/pulse every 2 h
sc for a total of 9 consecutive days), when the patient had reached his
targetheightof177cmandabodyweightof69kg.Thistestingwasdone
7 wk after the last injection of testosterone. Pituitary gonadotropin
secretionwasstimulatedneitherbylowdosepulsatileGnRH,norbythe
acute administration of 100 mg GnRH iv bolus (Table 1), demonstrating
a pituitary participation to the defect.
Of note, the patient also presented an initial episode of catatonic
schizophrenia at age 19, when he started to work as a professional cook.
This episode required a brief stay in a psychiatric hospital at that time,
but the patient was discharged on no medication. He was subsequently
unable to cope with a regular job, and more recently suffered from
recurrent attacks of catatonia. The diagnosis of schizophrenic disorder
was made, and the patient is now being treated with haloperidol de-
canoate. His social adaptation remains very poor: he does not have a
regular employment, and still lives with his parents.
PCR and direct DNA sequencing of DAX-1 gene
The following studies were approved by the ethical committee of our
institution, and formal informed consent was obtained from the patient
and all members of his family. Control DNA was obtained from two
normalvolunteers.GenomicDNAwasextractedfrombloodleukocytes,
using commercially available reagents (Nucleon BACC2, Amersham
Pharmacia Biotech, Little Chalfont, UK). Overlapping genomic DNA
fragments encompassing the two exons of the DAX-1 gene as well as 4
kb of the 3untranslated region were obtained by PCR, using the fol-
lowing sets of forward and reverse primers (each primer is identified by
a number corresponding to the nucleotide coordinates of the GenBank
accession no. U31929, and a letter that indicates the strand orientation,
either F for forward or R for reverse):
1523F: 5TAAATAGGTCCCAGGAGGCAG
1869F: 5CCGAGGCGACGCTGGGTCCGTG
4499F: 5GCCTCTCTTTGCTGTTTATCC
6074F: 5AGCTAGCAAAGGACTCTGTGG
7904F: 5GAAAGCTTCCAGAAGCAGTTC
2133R: 5TCTTTACCCCCTGGCCTCTGC
2316R: 5GAGACCACGCGACGCCGGCCA
2799R: 5CCGATGCTTTTGTGAGCTGGG
6419R: 5CATGGTGAACTGCACTACT
8847R: 5TCACAGATCCTAATTCCCTGG
PCRs were performed in a final volume of 50 l, using: 200 ng of
genomic DNA, 5 pmol of each primer, 50 pmol of each deoxy-NTP, 60
mmTris-SO4,18mm(NH4)2SO4,1.5mmMgSO4,and1loftheElongase
enzymemix(LifeTechnologies,Inc.,Gaithersburg,MD).Reactionswere
run for 30–35 cycles in a Perkin-Elmer (Foster City, CA) 9700 apparatus.
Length of extension times and annealing temperatures varied and were
optimized according to, respectively, the size of the specific PCR-prod-
uct and the set of primer pair used.
All sequencing reactions, including direct DNA sequencing of PCR
products, were performed by Microsynth (Balgach, Switzerland) using
an automated sequencer. For improved accuracy and precision, se-
quences of PCR fragment products were determined in both directions.
Alignments and comparisons between the wild-type DAX-1 gene and
mutated DAX-1 gene were done using the programs BestFit and PileUp
from the GCG sequence analysis package (Genetics Computer Group,
Madison, WI).
Southern blot analysis
Genomic DNA (10 g) from the proband and normal controls was
digested with EcoRI, then separated through a 1% agarose gel. The DNA
was transferred onto a nylon membrane (Hybond-N
, Amersham Phar-
maciaBiotech),fixedbyUVcross-linkingandsubjectedtohybridization
to a
32P-labeled probe homologous to the last 944 nucleotides of the
DAX-1 gene. This probe was generated by PCR, employing the 7904F
and 8847R primer pairs and
32P-labeled by using a random priming kit
(Roche, Rotkreuz, Switzerland), under conditions suggested by the
manufacturer.
Construction of plasmids
The expression vector coding for the new putative form of DAX-1
protein of the proband, was constructed by cloning a PCR-generated
genomic DNA fragment into the pcDNA3 mammalian expression plas-
mid. This fragment starts 30 nucleotides upstream of the starting ATG
and extends into the intronic sequence that follows exon 1, terminating
at the first intronic EcoRI site of the gene (position 3428). The amplifi-
cation primers used were respectively: 5AGGAGGATCCACTGGG-
CAGAACTGGGC (forward sequence, coordinates 1546–1562) and
5AGGAGAATTCTAAAATACAGTGCTCCTGC(reversesequence,co-
ordinates 3428–3404). BamHI and EcoRI sites used for the directional
cloning are underlined.
Alltheotherplasmidsusedinthisstudyhavealreadybeendescribed
elsewhere (11, 19). Briefly, the firefly luciferase reporter construct UAS-
TK109luc contains two yeast transcription factor GAL4 upstream acti-
vating sequence (UAS) sites upstream of the 109 TK promoter, and the
TABLE 1. Lack of stimulation of gonadotropin secretion by acute
administration of GnRH (100 g iv), either at baseline or after
several days of administration of pulsatile GnRH
Baseline Day 4
GnRH 5 gq2h
Day 7
GnRH 10 gq2h
0 min 60 min 0 min 60 min 0 min 60 min
LH (IU/liter) 0.5 0.5 0.5 0.5 0.5 0.5
FSH (IU/liter) 0.4 0.4 0.4 0.4 0.5 0.6
FAS (IU/liter) 0.17 0.18 0.16 0.13 0.16 0.14
T (nmol/liter) 2.0 1.7 1.1
E2 (nmol/liter) 0.09 0.09 0.09
Testing was performed 7 wk after withdrawal of testosterone ester
supplementation.
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acute regulatory protein (StAR). GAL-SF-1 contains the first 147 amino
acids of GAL4 [representing the DNA binding domain (DBD)] fused to
the mouse SF-1 devoid of its own DBD (residues 133–463). The control
vector GAL4-DBD contains only the DBD. The full-length mouse SF-1
cDNA was cloned into the pBKCMV expression plasmid (Stratagene, La
Jolla, CA) as well as the wild-type full-length human DAX-1. 347–470
is a carboxy-terminal deletion mutant of human DAX-1, also cloned into
the pBKCMV backbone.
Cell culture, transient transfections, and luciferase assays
The human choriocarcinoma cell line JEG-3 was used for all trans-
fection experiments. These cells were grown in DMEM supplemented
with 7.5% fetal bovine serum (Life Technologies, Inc.) in a 5% CO2
atmosphereat37C.JEG-3cellswereseededon12-wellplatesatadensity
of about 2  10
5 cells/well and transiently transfected by the calcium
phosphatetechniqueemployingtheProFectionmammaliantransfection
system kit (Promega Corp., Madison, WI), according to the manufac-
turer’sinstructions.Eachwellwascotransfectedwith1gofthespecific
firefly luciferase plasmid reporter, 5 ng of the Renilla luciferase reporter
pRL-TK (Promega Corp.), and varying amounts of expression plasmids
asspecifiedinthefigurelegends.Theuseofthesecondplasmidreporter
that encodes for the Renilla luciferase under the control of the thymidine
kinase promoter conveniently allows for the normalization of all results
according to transfection efficiency of each individual sample within the
same luciferase assay. Total amount of DNA was kept constant by
complementing each transfection with empty backbone plasmid when
needed (either pBKCMV or pcDNA3). Luciferase assays were per-
formed 48 h after transfection using the Dual Luciferase Reporter Assay
System (Promega Corp.), according to the manufacturer’s instructions.
Luminescence was measured with a Turner Designs Luminometer
Model TD-20/20 (Promega Corp.). Results are reported as a percentage
of luciferase activity of either the GAL4-SF-1 or SF-1 expression vectors
to allow comparison of data from different experiments (means  se
of at least three separate experiments, each consisting of triplicate
transfections).
Western blot analysis
Aliquots of the protein extracts prepared from transfected JEG-3 cells
were assayed by Western blot analysis employing a monoclonal anti-
body specific for DAX-1. This antibody (2F4) was raised against a pep-
tide corresponding to amino acids 135–166 of the human DAX-1 protein
(20).Equalamountsofproteinswereseparatedonto10%SDS-PAGEand
transferred to a polyvinylidene difluoride membrane. Antibody com-
plexes were visualized by the ECL system (Amersham Pharmacia Bio-
tech, Arlington Heights, IL).
Results
Mutation analysis
To search for mutations in DAX1, genomic DNA from the
proband was subjected to PCR amplification followed by
direct sequencing of the PCR products. A panel of primer
pairs was designed to span the two exons of the DAX-1 gene
(see Fig. 2 and below). Failure to obtain the expected PCR
product in the proband with a primer pair designed to am-
plify exon 2 (6074F and 6419R) suggested the presence of a
deletion in this region. This hypothesis was further con-
firmed by Southern blot analysis, as displayed in Fig. 2A:
usingasaprobea944bp-longDNAfragmentcorresponding
to the terminal part of the gene (coordinates 7904 to 8847, see
Subjects and Methods), we could detect a correctly sized 4022
bp-long band in the EcoRI restricted DNA prepared from
normal controls. Instead, the EcoRI digested DNA prepared
from the proband yielded a shorter band, slightly larger than
3 kb in size. These results were interpreted as consistent with
the presence of a deletion eliminating the EcoRI site located
at position 4825 of the DAX-1 gene.
We were then able, using the 4499F and 8847R set of
primers, to amplify a 2108-bp fragment from the genomic
DNA of the proband whereas in normal controls, the same
set of primers amplified a 4349-bp fragment (Fig. 1B). This
result confirmed the suspected presence of a deletion of
about 2.2 kb in the DAX-1 gene of the proband. His mother
was heterozygous for the deletion (Fig. 1C), whereas his
unaffected brother and father both carried a normal allele
(Fig. 1C). Direct sequencing of the amplified fragments re-
vealed that the deletion extends from position 4561 through
position 6801, completely eliminating exon 2 of the gene. In
addition, an insertion of a short stretch of 27 bp at the site of
deletion was present (Fig. 2).
Next, we tried to verify the possibility that the 2.2-kb
deleted fragment could be present in other regions of the
chromosomes due to a translocation event, as suggested by
homology of the 27-bp insertions with a region on chromo-
some5.However,fluorescentinsituhybridizationanddirect
PCR amplification of genomic DNA with primers located
inside of the deletion failed to yield positive results (data not
shown).
Of note, during the course of sequencing, we found that
the 10th nucleotide of the first exon of the proband did not
correspond to the published GenBank sequence (U31929): a
C was replaced by a G (data not shown). If correct, this C 3
G substitution in the first nucleotide of the fourth codon
would result in a Q4E missense mutation. However, this
could represent a mistake in the published sequence rather
than a real missense mutation, as the same substitution was
also found in all controls tested (data not shown).
Functional analysis of the new mutated form of DAX-1
protein produced by the deleted gene
As described above, mutation analysis showed the com-
plete lack of exon 2 of DAX-1 in the proband. Thus, the
transcription of this deleted form of DAX-1 would generate
atruncatedproteinlackingthelast81aminoacids,whichare
encoded by exon 2. However, because the natural splice
acceptor site is eliminated by the deletion as well, it can be
predicted that the 119 bp-long intronic sequence that hap-
pens to be in frame with exon 1 could be translated. This
would result in a protein that has a new, 40 amino acid-long
carboxy-terminal end replacing the wild-type sequence en-
coded by exon 2. To analyze the functionality of this new
putative form of mutated DAX-1, we cloned a stretch of
genomic sequence containing exon 1 plus the first 681 nu-
cleotides of intronic sequence terminating at an EcoRI site
into the pcDNA3 mammalian expression vector, and tested
it in transient transfection experiments.
Transfection assays were based on the well characterized
transcriptional silencing activity of wild-type DAX-1 on the
function of the transcriptional activator orphan nuclear re-
ceptor SF-1. As controls, we used expression vectors coding
for wild-type human DAX-1 and the 347–470 DAX-1
carboxy-terminal deletion mutant, lacking the last 124 amino
acids (11). In the first assay format, we used a native pro-
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reporter gene was driven by the human StAR promoter. This
promoter contains three putative SF-1 sites, which are func-
tionallyresponsivetoSF-1.Inaddition,DAX-1caninhibitthe
activity of this promoter through an alternative mechanism
that appears to be independent of SF-1 (21). As shown in Fig.
2, this promoter is robustly stimulated (20-fold stimulation
with respect to the reporter/empty vector) by an SF-1 ex-
pression construct (mouse SF-1 cDNA downstream of the
CMV promoter). Cotransfection of increasing amounts of
wild-type DAX-1 (5, 10, and 20 ng) greatly reduced the stim-
ulatory activity of SF-1, reaching 95% of repression of SF-1-
mediated transactivation at the highest DNA dose. As
expected, the 347–470 DAX-1 deletion control was capable
of only partially inhibiting SF-1 activity, with a repression of
37%, 50%, and 62%, respectively, at the increasing doses
of DNA. In contrast, the construct expressing the mutant
DAX-1 of the proband produced absolutely no repression at
the 5 ng dose, 10 ng of DNA caused only 11% inhibition, and
a 53% inhibition of SF-1-mediated transcription was reached
at the highest dose of DNA. Therefore, repressor activity of
the mutated DAX-1 protein described here was lower than
the previously described 347–470 deletion mutant (11).
Western blot analysis of the protein extracts from JEG-3
transfected cells and using a DAX-1 specific monoclonal
antibody demonstrated the production of mutant DAX-1
proteins of the expected size (shown as inset in Fig. 3).
We also assayed the function of proband DAX-1 on the
UAS-TK109luc reporter (data not shown), which is an arti-
ficial promoter containing two GAL4 sites upstream of the
FIG. 1. A, Southern blot analysis of an EcoRI digestion of genomic DNA, demonstrating an abnormal digestion pattern in the proband. Left
arrow indicates the position of the wild-type band as in control 1 (CT1) and 2 (CT2). Right arrow indicates the presence, in the DNA prepared
from the proband, of a shorter fragment hybridizing with the same probe. B, PCR analysis of the genomic DNA from the proband and two
unrelated controls (CT1 and CT2), demonstrating the existence of a 2.2-kb deletion in the proband. A schematic depiction of the PCR assay
isshownontheleftside.C,GenotypingoftherestofthefamilybythesamePCRanalysisasabove.Thisgelshowsthatthemotherisheterozygote,
whereas the brother and father carry a wild-type DAX-1 allele.
FIG. 2. Schematic representation of
the genetic rearrangement of DAX-1 in
the proband. Direct sequencing of
genomic DNA allowed to identify a
2240-bp deletion combined with a 27-bp
insertionatthesiteofdeletion.Position
ofthevariousprimerpairsusedforPCR
amplification of genomic DNA is shown
on the wild-type DAX-1 gene.
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basically mirrored the results obtained with the assay em-
ploying the native promoter. Cotransfection of SF-1 pro-
duced a 20-fold increase in activation over the empty vector.
Coexpression of wild-type DAX-1 was able to repress this
activation in a dose-dependent manner, with complete re-
pression of SF-1-mediated stimulation at a 20-ng dose. Sim-
ilar doses of the 347–470 construct and the proband mutant
construct inhibited transactivation by only 62% and 53%,
respectively.
Discussion
In the present study, we describe an unusual case of ad-
renal insufficiency caused by a complex mutation of DAX-1,
associated later in life with hypogonadotropic hypogonad-
ism of pituitary origin. Similar to previously published pa-
tients (14), adrenal insufficiency was diagnosed early after
birth on the occasion of the work-up of a severe salt-losing
state. The clinical history of this patient is remarkable for the
subsequent recovery of a sufficient adrenal reserve to allow
full withdrawal of all hormonal supplementation for over 6
months. Heterogeneity both in the age at diagnosis as well
as in the severity of the adrenal syndrome is a well recog-
nized feature of DAX-1 deficient patients (13, 14, 22, 23). In
the patient presented here, persistence of residual adrenal
function more than 2 yr after birth suggests that a milder
phenotype was associated with that particular mutation, at
least with respect to the onset of the disease. That adrenal
insufficiency of DAX-1 patients can spontaneously evolve
toward a transiently compensated state has already been
described (17, 18). Our similar finding suggests that such
clinical course might be more frequent than initially envi-
sioned. This possibility should therefore be kept in mind by
physicians taking care of these patients, as it could bear
significant implications for their clinical management.
Variability in the hypogonadic syndrome that classically
accompanies adrenal insufficiency has also been reported
(24). There is evidence in the literature for a purely hypo-
thalamic origin of the defect (25), for a pituitary origin (26,
27) or for both (28). Therefore, the effects of pulsatile GnRH
administered at physiological doses were assessed in this
patient. In addition, the response to stimulation with phar-
macologicalconcentrationsofthedecapeptidewasalsoeval-
uated. Neither physiological, nor pharmacological stimula-
tion with GnRH was found to stimulate gonadotropin
secretion, demonstrating the participation of pituitary go-
nadotrope cells to the hypogonadism. It should be noted,
however, that these results do not exclude a hypothalamic
component.
This patient was also recently diagnosed with schizophre-
nia, requiring multiple hospitalizations in a psychiatric set-
ting over the last year. Such phenotypic trait has never been
reported previously in DAX-1 patients. Interestingly, his
mother is affected by a milder psychotic disorder. However,
his brother who carries a wild-type DAX-1 allele also suffers
from mild psychosis, suggesting that the mental disease may
FIG. 3. Effectofthemutatedproteinon
SF-1-mediated transcription. A sche-
maticdepictionofthetransientcotrans-
fectionassayformatisshownatthetop,
right corner: an SF-1 expression vector
is able to transactivate the StAR-luc re-
porter, which contains three SF-1 sites
of the native promoter. As expected,
wild-type (wt) DAX-1 dramatically de-
creased SF-1-mediated transcription
(bottom) in a dose-dependent fashion.
ProbandDAX-1(top),instead,showeda
loss of transcriptional silencing activ-
ity. DAX-1 deletion mutant 347–470,
used as control (middle, see Ref. 11),
exhibits intermediate silencing activ-
ity.Results(means SEofatleastthree
separate experiments, each consisting
of triplicate transfections) are reported
asapercentageoftheluciferaseactivity
due to SF-1 in the absence of any
DAX-1. The activity of the StAR-luc re-
porter alone is shown in the last bottom
bar.Insetinthetopleftcornershowsthe
DAX-1proteinformspresentinthecells
transfected with the respective expres-
sion vectors, as detected by Western
blot using a DAX-1 monoclonal
antibody.
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family.
Recent reports underline the importance of DAX-1 for
normal human spermatogenesis (13, 24). This finding is con-
sistent with the phenotype of the mouse model of DAX-1
deficiency (12). In this context, a testicular biopsy is desirable
in all DAX-1 deficient patients, and even probably indicated
in the work-up of their infertility. The psychiatric disorder
affectingthepatientunderdiscussionprecludedanyattempt
to obtain a testicular biopsy.
The human mutations affecting DAX-1 have been sum-
marized recently (14, 15). They have in common to cause a
loss of the carboxy-terminal end of the DAX-1 protein. The
vast majority of them are single base pair insertions or de-
letions, resulting in frameshift and premature stop codons
(14, 15). This is consistent with in vitro data attributing the
transcription repressor activity of DAX-1 to its carboxy-
terminal part (11). In addition, some of the reported muta-
tions are missense (15). These have been particularly useful
in structure-function analyses, thus helping to identify im-
portant residues in the protein. However, when considering
all available information regarding the clinical presentation
of the adrenal insufficiency or of the hypogonadism, there is
no clear correlation between the type of mutation and the
phenotypeexceptintherarelate-onsetcasesduetomissense
mutants.
We report here for the first time a complex genetic rear-
rangement within DAX-1, combining a 2.2-kb deletion en-
compassing part of the intron as well as the entire second
exon with a small insertion of a 27-bp fragment. Because of
the presence of a small insertion at the site of deletion, we
initially hypothesized that this rearrangement could result
from an imbalanced translocation. And indeed, the Xp2.21
region of the X chromosome where DAX-1 is located seems
to be particularly prone to such events. Consistent with this
hypothesis,BLASTanalysisofthe27-bpfragmentinsertedat
the site of the deletion indicated the existence of a highly
homologous region on human chromosome 5. Thus, we at-
temptedtodemonstratethatthemissing2.2-kbfragmentwas
still present in the genome of the patient. This was done with
two different experimental approaches: fluorescent in situ
hybridization and direct PCR amplification of genomic
DNA. However, both methods yielded negative results, sug-
gesting that the 2.2-kb fragment has indeed been deleted
from the genome of this patient.
Wild-type DAX-1 encodes for a 470-amino acid protein.
The putative protein synthesized by the mutated DAX-1
gene described here will lack all the residues encoded by
exon 2. These correspond to the last 81 amino acids located
at the C-terminal extremity of the wild-type DAX-1 protein.
In addition, because of the deletion of the entire exon 2, the
mutated gene will also lack the splice acceptor site of that
exon. It could therefore be hypothesized that transcription
will continue after the end of exon 1 and into the intron, until
the next stop codon is reached. Sequence analysis of the
intronic sequence immediately adjacent to exon 1 demon-
strates the existence of a stop codon located 120 bp down-
stream of the 3 end of the exon. Therefore, the putative
protein produced by this mutated DAX-1 gene should be 429
amino acids long: the initial 389 residues at the N-terminal
extremity, encoded by the first exon, would correspond to
the wild-type sequence, whereas the last 40 amino acids
should be completely unrelated to the wild-type sequence,
being transcribed from the intronic sequence immediately
adjacent to the 3 end of exon 1. Western blot experiments
seem to support this hypothesis, by showing the production
of mutant DAX-1 proteins of the expected size. In vitro func-
tionalanalysesconfirmthegreatlyreducedrepressoractivity
exerted by such mutant protein. Therefore, our findings are
entirely consistent with previous data, showing that the re-
pressor domain of DAX-1 is located at its carboxy-terminal
end (11, 16). With respect to previously published inactivat-
ing mutations of DAX-1, the mutation reported here has the
most dramatic effect on the function of the protein, resulting
in a complete loss of any measurable biological activity.
In conclusion, we describe here a male patient harboring
anovelandcomplexrearrangementofDAX1,whopresented
an unusual evolution of adrenal insufficiency during in-
fancy. Therefore, this case expands the spectrum of clinical
presentation of adrenal insufficiency in AHC patients.
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